Khondrion reports successful outcome of KH176 Phase 1 Clinical trials

4/12/15 - NIJMEGEN – Khondrion, the Dutch biopharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, announces today the successful completion of its Phase 1 Clinical trials with its lead compound KH176. KH176 is an orally bio-available small molecule developed by Khondrion for the treatment of mitochondrial (-related) diseases. Read the full press release here.

Search Results